Partnership, Quarterly Reports, Acquisition, and Publication - Research Report
on Alere, Ironwood, Magellan Health Services, Foundation Medicine, and
NEW YORK, October 28, 2013
NEW YORK, October 28, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Alere Inc.
(NYSE: ALR), Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), Magellan Health
Services Inc. (NASDAQ: MGLN), Foundation Medicine, Inc. (NASDAQ: FMI), and
InterMune Inc. (NASDAQ: ITMN). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.
Alere Inc. Research Report
On October 23, 2013, Alere Inc. (Alere) announced an educational partnership
with the Alliance for the Prudent Use of Antibiotics (APUA) to expand the
impact of Alere's new Test Target Treat campaign website. According to Alere,
APUA will provide non-commercial, expert educational material for the
Company's antimicrobial stewardship initiative. Alere reported that the new
website will broaden the distribution of APUA's standard non-commercial
messages and will boost global awareness of antibiotic resistance and
effective interventions. The Full Research Report on Alere Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
Ironwood Pharmaceuticals, Inc. Research Report
On October 22, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) released Q3
2013 results. Ironwood registered revenues of $4.9 million in Q3 2013, down
compared to revenues of $96.4 million in Q3 2012. The Company reported net
loss of $61.8 million in Q3 2013, compared to net income of $47.6 million in
Q3 2012. Ironwood's diluted loss per share was $0.51 in Q3 2013, compared to
diluted EPS of $0.42 in Q3 2012. Peter Hecht, CEO of Ironwood, stated, "This
quarter, we continued to make good progress across our key value drivers.
LINZESS is performing well across the key leading indicators, reinforcing the
significant opportunity we see ahead. Our scientists continue to advance the
pharmacology of linaclotide and explore its utility more broadly while also
progressing our broader pipeline, and our global partners are making important
strides in bringing linaclotide to appropriate patients worldwide." The Full
Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/dbc4_IRWD]
Magellan Health Services Inc. Research Report
On October 1, 2013, Magellan Health Services Inc. (Magellan Health Services)
announced that it has successfully completed its acquisition of Partners Rx, a
privately held, full-service commercial pharmacy benefits management company
(PBM) with a strong focus on health plans and self-funded employers. Barry M.
Smith, CEO of Magellan, commented, "Our acquisition of Partners Rx will
enhance our full-service PBM capabilities by adding scale, relationships and
expertise." Smith added, "It complements our unique medical pharmacy and
specialty pharmacy capabilities, and will enable us to expand our presence in
the marketplace." Magellan Health Services reported that it paid $100 million
from existing cash on hand. The Full Research Report on Magellan Health
Services Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
Foundation Medicine, Inc. Research Report
On October 20, 2013, Foundation Medicine, Inc. (Foundation Medicine) announced
that results from a 24-month, multi-institution collaboration demonstrating
the analytic validation of its cancer genomic profiling assay, FoundationOne,
were published in the current online edition of Nature Biotechnology.
According to Foundation Medicine, FoundationOne is a comprehensive,
next-generation sequencing (NGS) based test used to characterize all classes
of molecular alterations (base substitutions, short insertions and deletions
(indels), copy number alterations and select rearrangements) across 287
cancer-related genes from routine formalin-fixed, paraffin-embedded (FFPE)
clinical specimens. The Company reported that the publication also describes
clinical application of this assay across 2,221 consecutive patient cases. The
Full Research Report on Foundation Medicine, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d9a0_FMI]
InterMune Inc. Research Report
On October 23, 2013, InterMune Inc. (InterMune) announced that it will release
its Q3 2013 results after the US markets close on Wednesday, October 30, 2013.
InterMune reported that the Q3 2013 live conference call will be held on the
same day at 4:30 p.m. ET. The Company stated that interested parties may
access the live call and its replay through its website. The Full Research
Report on InterMune Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
Press spacebar to pause and continue. Press esc to stop.